Prognosis
J&J One-Shot Vaccine Grants Lasting Response in Early Study
- Immune responses lasted through end of the 71-day trial
- Findings bode well for J&J’s large ongoing efficacy study
This article is for subscribers only.
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance.
More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial.